30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: TiGenix

ChondroCelect €1.04MM (~US $1.35MM), +55% from

  • Obtained reimbursement in Spain
  • Growth supported by continued uptake in Belgium, Netherlands
  • Renewed license for stem cell manufacturing facility in Madrid